Jasper Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Jasper Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Jasper Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$19.9M, a 2.72% decline year-over-year.
  • Jasper Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$68.7M, a 5.85% decline year-over-year.
  • Jasper Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$68.9M, a 34.5% decline from 2022.
  • Jasper Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$51.2M, a 39% decline from 2021.
  • Jasper Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$36.8M, a 78.1% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$68.9M -$17.7M -34.5% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-05
2022 -$51.2M -$14.4M -39% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-05
2021 -$36.8M -$16.2M -78.1% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-08
2020 -$20.7M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.